Reach for the Right Vial when testing for CT/NG


Sonora Quest Laboratories has moved to APTIMA Combo 2® for CT/NG testing



High Sensitivity and Specificity for You and Your Patients

Using highly sensitive nucleic acid amplification test (NAAT) technology, APTIMA offers high sensitivity and specificity due to its ability to target and amplify ribosomal RNA, enabling the detection of trace amounts of CT/NG infection.

Estimated Number of New Infections in the United States, 2013¹



Bars are for illustration only; not to scale, due to wide range in number of infections.

Current CDC Screening Recommendations for Chlamydia trachomatis

- All sexually active women aged
 25 and younger^{2,3}
- All pregnant women should be screened at their first visit⁴
- Those at high risk for infection ^{2,3}

The Importance of Screening

- Over 50% of chlamydia and gonorrhea infections are asymptomatic⁵
- Left untreated, CT/NG may lead to serious complications such as PID, infertility and pre-term birth 6











Excellent Sensitivity and Specificity Across Multiple Specimen Types 7[^]

		APTIMA Assay Technology ⁷			
Specimen Type	Chlamydia		Gonorrhea		
	Sensitivity	Specificity	Sensitivity	Specificity	
ThinPrep® liquid-based Pap					
	96.7%	99.2%	92.3%	99.8%	
APTIMA® Vaginal Swab Collection Kit - Supply #23960					
	Clinician-collected				
	96.6%	96.8%	96.0%	99.2%	
	Patient-collected				
	98.4%	96.8%	100%	99.5%	
APTIMA® Unisex Collection Kit (for endocervical and male urethral specimens) - Supply #22127					
APTIMA Section in Sect	Endocervical				
	94.2%	97.6%	99.2%	98.7%	
	Urethral (Male)				
	95.9%	97.5%	99.1%	97.8%	
APTIMA® Urine Collection Kit - Supply #20122 Fill between the black lines to prevent sample rejection					
	Urine (Female)				
	94.7%	98.9%	91.3%	99.3%	
	Urine (Male)				
	97.9%	98.5%	98.5%	99.6%	

 $^{{}^{\}wedge}\text{Not}$ all sample types are FDA-cleared, see table for performance claims.

CT/NG Testing Options from Sonora Quest Laboratories**

Test	Test Code	CPT Code(s)*
Chlamydia trachomatis, APTIMA Device	903150	87491
N. gonorrhoeae, APTIMA Device	903151	87591
Chlamydia trachomatis/N. gonorrhoeae, APTIMA Device	904767	87491; 87591
Chlamydia trachomatis, ThinPrep Vial	906394	87491
N. gonorrhoeae, ThinPrep Vial	906395	87591
Chlamydia trachomatis/N. gonorrhoeae, ThinPrep Vial	803509	87491; 87591

References

- 1. Genters for Disease Control and Prevention 2013. http://www.cdc.gov/std/stats/ STI-Estimates-Fact-Sheet-Feb-2013.pdf
- $2.\,\mathsf{CDC}\,\mathsf{Morbidity}\,\mathsf{and}\,\mathsf{Mortality}\,\mathsf{Weekly}\,\mathsf{Report},\mathsf{December}\,\mathsf{17,2010}\,\mathsf{/}\,\mathsf{Vol}.\,\mathsf{59}\,\mathsf{/}\,\mathsf{No}.\,\mathsf{RR-12}.$
- 3. The American College of Obstetricians and Gynecologists Committee Opinion Number 483 April 2011.
- 4. Centers for Disease Control and Prevention. http://www.cdc.gov/std/treatment/2010/ specialpops.htm
- Centers for Disease Control and Prevention (CDC). 2007 Sexually Transmitted Diseases Surveillance http://www.cdc.gov/std/stats07/womenandinf.htm
- Centers for Disease Control and Prevention (CDC). Tracking the hidden epidemic: Trends in STDs in the United States, 2000. http://www.cdc.gov/std/Trends2000/trends2000.pdf.
- 7. 2011 APTIMA COMBO 2 Assay [package insert], San Diego, CA; Gen-Probe, 2011.

*The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.

**If initial test on patients <14 years is positive an alternate target will be performed at an additional charge (CPT code(s): 87491 and/or 87591).

Sonora Quest Laboratories, the associated logo and marks are the registered trademarks of Sonora Quest Laboratories. All third party marks — '©' and '™ — are the property of their respective owners. © 2014 Sonora Quest Laboratories. All rights reserved.





